[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2122764T3 - Inhibidor de la proteina quinasa c. - Google Patents

Inhibidor de la proteina quinasa c.

Info

Publication number
ES2122764T3
ES2122764T3 ES96308318T ES96308318T ES2122764T3 ES 2122764 T3 ES2122764 T3 ES 2122764T3 ES 96308318 T ES96308318 T ES 96308318T ES 96308318 T ES96308318 T ES 96308318T ES 2122764 T3 ES2122764 T3 ES 2122764T3
Authority
ES
Spain
Prior art keywords
inhibitor
quinase
protein
protein quinase
indolilmaleimida
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96308318T
Other languages
English (en)
Inventor
Gary Lowell Engel
Nagy Alphonse Farid
Margaret Mary Faul
Michael Robert Jirousek
Lori Ann Richardson
Leonard Larry Winneroski Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2122764T3 publication Critical patent/ES2122764T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA NUEVOS DERIVADOS MACROCICLICOS DE BIS-INDOLILMALEIMIDA, DE FORMULA: Y SOLVATOS DE LOS MISMOS. LA INVENCION PROPORCIONA ADEMAS EL METODO DE PREPARACION, FORMULACIONES FARMACEUTICAS Y METODOS DE UTILIZACION PARA INHIBIR LA PROTEINA QUINASA C EN MAMIFEROS.
ES96308318T 1995-11-20 1996-11-18 Inhibidor de la proteina quinasa c. Expired - Lifetime ES2122764T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US697095P 1995-11-20 1995-11-20

Publications (1)

Publication Number Publication Date
ES2122764T3 true ES2122764T3 (es) 1998-12-16

Family

ID=21723527

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96308318T Expired - Lifetime ES2122764T3 (es) 1995-11-20 1996-11-18 Inhibidor de la proteina quinasa c.

Country Status (34)

Country Link
US (3) US5710145A (es)
EP (1) EP0776895B1 (es)
JP (1) JP3348859B2 (es)
KR (1) KR100304210B1 (es)
CN (1) CN1093759C (es)
AR (2) AR004717A1 (es)
AT (1) ATE172199T1 (es)
AU (1) AU711125B2 (es)
BR (1) BR9611724A (es)
CA (1) CA2237221C (es)
CO (1) CO4750823A1 (es)
CY (1) CY2103B1 (es)
CZ (1) CZ297524B6 (es)
DE (1) DE69600784T2 (es)
DK (1) DK0776895T3 (es)
EA (1) EA000967B1 (es)
EG (1) EG23871A (es)
ES (1) ES2122764T3 (es)
HU (1) HU226821B1 (es)
IL (1) IL124417A (es)
MX (1) MX9803792A (es)
MY (1) MY118068A (es)
NO (1) NO310196B1 (es)
NZ (1) NZ323571A (es)
PE (1) PE22798A1 (es)
PL (1) PL184715B1 (es)
RO (1) RO120074B1 (es)
SI (1) SI0776895T1 (es)
TR (1) TR199800759T2 (es)
TW (1) TW403754B (es)
UA (1) UA61897C2 (es)
WO (1) WO1997018809A1 (es)
YU (1) YU49315B (es)
ZA (1) ZA969646B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
JP3646651B2 (ja) * 1998-01-30 2005-05-11 ダイソー株式会社 ブタントリオール誘導体の製造法
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
US6291446B1 (en) * 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
US6225301B1 (en) * 1998-03-05 2001-05-01 Eli Lilly And Company Therapeutic treatment for renal dysfunction
JP2002506868A (ja) * 1998-03-13 2002-03-05 ザ ユニバーシティー オブ ブリティッシュ コロンビア 癌治療において用いるためのグラニュラチミド誘導体
CA2245029A1 (en) 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
SE9800835D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
US6706721B1 (en) * 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6284783B1 (en) 1999-06-09 2001-09-04 The Uab Research Foundation Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US7087613B2 (en) * 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6852688B2 (en) 2000-03-10 2005-02-08 University Of Florida Compositions for treating diabetic retinopathy and methods of using same
US20030224415A1 (en) * 2001-06-29 2003-12-04 Gala Design, Inc. Selection free growth of host cells containing multiple integrating vectors
CA2413156C (en) * 2000-07-03 2009-08-18 Gala Design, Inc. Expression vectors
AU2001271614B2 (en) * 2000-07-03 2007-05-31 Catalent Pharma Solutions, Llc Host cells containing multiple integrating vectors
US6300106B1 (en) * 2000-11-22 2001-10-09 Ppg Industries Ohio, Inc. Method of preparing 3-[2-{(Methylsulfonyl)oxy}-ethoxy ]-4-(triphenylmethoxy)-1-butanol, methane sulfonate
US7384738B2 (en) * 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
US20040038304A1 (en) * 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
AU2003241398A1 (en) * 2002-05-06 2003-11-17 Washington University Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
DE10244453A1 (de) * 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7232842B2 (en) * 2003-01-10 2007-06-19 Board Of Trustees Of The Leland Stanford Junior University Kinase inhibitors and associated pharmaceutical compositions and methods of use
ES2338789T3 (es) 2003-06-18 2010-05-12 Tranzyme Pharma Inc. Antagonistas macrociclicos del receptor de motilina.
US20050152942A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20050221429A1 (en) * 2004-01-16 2005-10-06 Cardinal Health Pts, Llc Host cells containing multiple integrating vectors comprising an amplifiable marker
US9421175B2 (en) * 2004-03-17 2016-08-23 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
DE102004019413A1 (de) * 2004-04-19 2005-11-24 Phenos Gmbh Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten
US20090111786A1 (en) * 2004-12-03 2009-04-30 Glass Christopher K Compounds that Prevent Macrophage Apoptosis and Uses Thereof
US20070281988A1 (en) * 2004-12-20 2007-12-06 Cameron Norman E Combination Therapy for Vascular Complications Associated with Hyperglycemia
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
GB0504203D0 (en) * 2005-03-01 2005-04-06 Novartis Ag Organic compounds
US8158586B2 (en) * 2005-04-11 2012-04-17 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
US8508369B2 (en) 2006-09-01 2013-08-13 Intermec Ip Corp. RFID tag system with block coding, such as space-time block coding
AR069799A1 (es) * 2007-12-21 2010-02-17 Novartis Ag Composicion farmaceutica
EP2181999A1 (en) 2008-11-03 2010-05-05 Zentiva, A.S. Method of manufacturing ruboxistarin
US9265764B2 (en) * 2009-02-27 2016-02-23 Massachusetts Institute Of Technology Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
WO2011120911A1 (en) 2010-03-30 2011-10-06 Novartis Ag Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
EP2925366B1 (en) 2012-11-29 2018-02-21 Novartis AG Pharmaceutical combinations
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
CN110300584A (zh) 2016-12-19 2019-10-01 克罗马德姆公司 治疗色素沉着过度病症的方法
WO2018175302A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates targeting c-src with reduced exposure
EP3600440A1 (en) 2017-03-20 2020-02-05 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
HRP20240840T1 (hr) 2017-07-28 2024-10-11 Applied Therapeutics, Inc Pripravci i postupci za liječenje galaktozemije
WO2021222165A1 (en) 2020-05-01 2021-11-04 Applied Therapeutics, Inc. Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency
KR20230128175A (ko) * 2022-02-25 2023-09-04 주식회사 온코크로스 루복시스타우린을 포함하는 항암용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK75289A3 (en) * 1988-02-10 1998-05-06 Hoffmann La Roche Substituted pyrroles, their use for producing a drug, and the drug on their base
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
US5589472A (en) * 1992-09-25 1996-12-31 Vice; Susan F. Diindolo compounds and pharmaceutical compositions containing them
KR100340159B1 (ko) * 1993-12-07 2002-11-23 일라이 릴리 앤드 캄파니 단백질키나제c억제제
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
WO1997018809A1 (en) 1997-05-29
DK0776895T3 (da) 1999-06-23
TW403754B (en) 2000-09-01
EA199800374A1 (ru) 1998-10-29
US6015807A (en) 2000-01-18
PL326754A1 (en) 1998-10-26
YU60996A (sh) 1999-03-04
TR199800759T2 (xx) 2001-01-22
AU1054897A (en) 1997-06-11
SI0776895T1 (en) 1999-04-30
AR004336A1 (es) 1998-11-04
NO982182D0 (no) 1998-05-13
MY118068A (en) 2004-08-30
CZ150298A3 (cs) 1998-12-16
US5710145A (en) 1998-01-20
JP3348859B2 (ja) 2002-11-20
EA000967B1 (ru) 2000-08-28
HU226821B1 (en) 2009-11-30
CN1202825A (zh) 1998-12-23
EP0776895A1 (en) 1997-06-04
KR100304210B1 (ko) 2001-11-05
HUP9903377A3 (en) 2000-04-28
CA2237221C (en) 2003-03-25
CA2237221A1 (en) 1997-05-29
IL124417A (en) 2002-11-10
MX9803792A (es) 1998-09-30
EG23871A (en) 2007-11-27
PE22798A1 (es) 1998-05-11
CY2103B1 (en) 2002-04-05
YU49315B (sh) 2005-06-10
US6117861A (en) 2000-09-12
UA61897C2 (en) 2003-12-15
NO982182L (no) 1998-05-13
BR9611724A (pt) 1999-06-01
NO310196B1 (no) 2001-06-05
CZ297524B6 (cs) 2007-01-03
PL184715B1 (pl) 2002-12-31
KR19990067596A (ko) 1999-08-25
EP0776895B1 (en) 1998-10-14
ZA969646B (en) 1998-05-18
DE69600784D1 (de) 1998-11-19
NZ323571A (en) 1998-12-23
JPH11500149A (ja) 1999-01-06
HUP9903377A2 (hu) 2000-02-28
IL124417A0 (en) 1998-12-06
CO4750823A1 (es) 1999-03-31
DE69600784T2 (de) 1999-04-08
CN1093759C (zh) 2002-11-06
RO120074B1 (ro) 2005-08-30
AU711125B2 (en) 1999-10-07
ATE172199T1 (de) 1998-10-15
AR004717A1 (es) 1999-03-10

Similar Documents

Publication Publication Date Title
ES2122764T3 (es) Inhibidor de la proteina quinasa c.
MX9707431A (es) Inhibidores de la proteina cinasa c.
ES2162843T3 (es) Inhibidores de la proteina quinasa c.
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
ES2144192T3 (es) Nuevos derivados de 1-fenil-2-dimetil-amino-metil-ciclohexan-1-ol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
EA199900373A2 (ru) Фармацевтические композиции
DE69917663D1 (de) 2-methyl-thieno-benzodiazepin-formulierung
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
GEP20084346B (en) Protein kinase c inhibitors
TW371661B (en) Novel intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
ES2175661T3 (es) Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
ECSP961937A (es) Inhibidor de proteina quinasa "c"
ECSP961938A (es) Nuevos intermedios y su uso para preparar bisindolilmaleimidas con un puente n, n-caso x - 10386
ECSP982785A (es) Nuevos compuestos de tetrahidroizoquinoleinil- carboxamida, de formula (i) y procedimiento para su obtencion
ECSP972052A (es) Quinoxalinadionas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 776895

Country of ref document: ES